Health · FDA Approvals
FDA Approves Roche’s Wilserdly for ESR1-Mutated Advanced Breast Cancer
The oral drug, given with everolimus, cut the risk of progression or death by 62% in a phase III trial; a second decision is due Nov. 30.

The Food and Drug Administration has approved Roche’s Wilserdly (giredestrant), taken with everolimus, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, Roche said on Nov. 16. The approval covers disease that returned during or after endocrine-based adjuvant therapy, or that progressed on at least one endocrine-based regimen, and requires an FDA-authorized test to detect the mutation.
The approval rests on the phase III evERA trial, published in the New England Journal of Medicine. In patients with ESR1-mutated tumors, the combination lowered the risk of progression or death by 62% compared with standard endocrine therapy plus everolimus (hazard ratio 0.38). OncLive reports median progression-free survival of about 10 months versus 5.5 months, and that overall survival data were still immature.
OncLive lists stomatitis (47.3%), diarrhea, nausea, fatigue, pneumonitis and rash among the most common side effects in the giredestrant arm, and reports that the FDA authorized the FoundationOne Liquid CDx test to identify eligible patients. Roche says a separate application for early-stage breast cancer, based on the lidERA trial, has a decision date of Nov. 30. Neither source gave a price.
Sources
- Roche, Nov. 16, 2026 company release: approval, indication, evERA trial, 62% risk reduction, Nov. 30 decision date <https://www.roche.com/media/releases/med-cor-2026-11-16b>
- OncLive, Nov. 16, 2026: median PFS, side effects, companion diagnostic, immature survival data <https://www.onclive.com/view/fda-approves-giredestrant-plus-everolimus-for-er-her2-esr1-mutated-metastatic-breast-cancer>
This article was drafted with AI writing tools from the sources listed, checked by a review pass, supervised by the paper’s editors and published by Daniel Varrone. Corrections: editor@monochromechronicles.com
More from Health
Recommended Reading
About this story: Compiled by the The Monochrome Chronicles desk from the sources listed above. Our standards · Report an error · Follow on YouTube